GSK drug Breo now available in U.S.

Posted by David Bracken on November 1, 2013 

GlaxoSmithKline and its partner Theravance announced this week that Breo Ellipta, a medicine for treating chronic obstructive pulmonary disease, is now available to U.S. pharmacies.

Breo is currently made in the United Kingdom, but GSK expects to begin manufacturing the medicine at its Zebulon facility by the end of 2015. GSK also makes the respiratory treatment Advair in Zebulon, where it employs about 600 people.

GSK employs 4,000 at its North American headquarters in Research Triangle Park, which is home to many of the company’s workers who focus on respiratory products.

Under the terms of GSK’s 2002 agreement with Theravance, GSK is in line to receive a $30 million milestone payment following the launch of Breo in the U.S.

The Food and Drug Administration approved the drug in May.

The drug is a once-daily maintenance treatment for patients with COPD, including chronic bronchitis and emphysema.

News & Observer is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere in the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Commenting FAQs | Terms of Service